Equillium to Present at Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, announced that CEO Bruce Steel and CMO Krishna Polu will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 1:30 PM ET. This presentation will focus on Equillium's innovative efforts in treating severe autoimmune and inflammatory disorders, particularly through its product candidate itolizumab (EQ001). The live webcast can be accessed on the company’s website and will be available for replay for 30 days.

LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D., chief medical officer, will present at Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020.

Date:		Tuesday, June 2, 2020
Time:		1:30 PM Eastern Time | 10:30 AM Pacific Time
Location:		Virtual Webcast

A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need.

Equillium’s initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Equillium believes that itolizumab has the potential to be a best-in-class disease modifying therapeutic and is advancing itolizumab into clinical development in the following severe immuno-inflammatory disorders: uncontrolled asthma, acute graft-versus-host disease, and lupus nephritis. For more information, visit www.equilliumbio.com.

Investor Contact
+1-858-412-5302
ir@equilliumbio.com

Media Contact
Cammy Duong
Canale Communications
+1-619-849-5389
cammy@canalecomm.com

FAQ

What will Equillium present at the Jefferies Virtual Healthcare Conference on June 2, 2020?

Equillium will present insights on their clinical-stage biotechnology efforts focusing on innovative treatments for severe autoimmune and inflammatory disorders.

Who are the presenters for Equillium at the Jefferies Virtual Healthcare Conference?

The presenters for Equillium are CEO Bruce Steel and CMO Krishna Polu.

What time is Equillium's presentation at the Jefferies Virtual Healthcare Conference?

Equillium's presentation is scheduled for 1:30 PM Eastern Time on June 2, 2020.

How can I watch Equillium's presentation at the Jefferies Virtual Healthcare Conference?

A live webcast of the presentation will be available on Equillium's website under the Investors section.

What is itolizumab (EQ001) and its significance for Equillium?

Itolizumab (EQ001) is a clinical-stage monoclonal antibody that targets the CD6-ALCAM pathway, crucial for treating severe immuno-inflammatory diseases.